DK1603584T3 - Aplidine til behandling af multipelt myelom - Google Patents

Aplidine til behandling af multipelt myelom

Info

Publication number
DK1603584T3
DK1603584T3 DK04720081T DK04720081T DK1603584T3 DK 1603584 T3 DK1603584 T3 DK 1603584T3 DK 04720081 T DK04720081 T DK 04720081T DK 04720081 T DK04720081 T DK 04720081T DK 1603584 T3 DK1603584 T3 DK 1603584T3
Authority
DK
Denmark
Prior art keywords
aplidine
multiple myeloma
treatment
medicament
manufacture
Prior art date
Application number
DK04720081T
Other languages
Danish (da)
English (en)
Inventor
Joseph R Bertino
Daniel Medina
Glynn Thomas Faircloth
Constantine S Mitsiades
Kenneth Anderson
Nicholas Mitsiades
Original Assignee
Dana Farber Cancer Inst Inc
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Pharma Mar Sa filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of DK1603584T3 publication Critical patent/DK1603584T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK04720081T 2003-03-12 2004-03-12 Aplidine til behandling af multipelt myelom DK1603584T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45412503P 2003-03-12 2003-03-12
US52029303P 2003-11-14 2003-11-14
PCT/GB2004/001062 WO2004080477A1 (fr) 2003-03-12 2004-03-12 Aplidine utilisee dans le traitement du myelome multiple

Publications (1)

Publication Number Publication Date
DK1603584T3 true DK1603584T3 (da) 2009-01-05

Family

ID=32994545

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04720081T DK1603584T3 (da) 2003-03-12 2004-03-12 Aplidine til behandling af multipelt myelom

Country Status (20)

Country Link
US (1) US7381703B2 (fr)
EP (1) EP1603584B1 (fr)
JP (1) JP4584245B2 (fr)
KR (1) KR101160320B1 (fr)
AT (1) ATE406171T1 (fr)
AU (1) AU2004218883B2 (fr)
CA (1) CA2519789C (fr)
CY (1) CY1108599T1 (fr)
DE (1) DE602004016126D1 (fr)
DK (1) DK1603584T3 (fr)
ES (1) ES2312979T3 (fr)
IL (1) IL170136A (fr)
MX (1) MXPA05009742A (fr)
NO (1) NO334264B1 (fr)
NZ (1) NZ541611A (fr)
PL (1) PL1603584T3 (fr)
PT (1) PT1603584E (fr)
RU (1) RU2335294C2 (fr)
SI (1) SI1603584T1 (fr)
WO (1) WO2004080477A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1229922T1 (sl) * 1999-11-15 2008-04-30 Pharma Mar Sa Zdravljenje raka z aplidinom
JP2006519848A (ja) * 2003-03-12 2006-08-31 ファルマ・マール・ソシエダード・アノニマ 改良された抗腫瘍治療
WO2007100385A2 (fr) * 2005-10-31 2007-09-07 Genentech, Inc. Conjugués anticorps-médicaments à base de depsipeptide macrocyclique et méthodes associées
US8258098B2 (en) 2006-02-28 2012-09-04 Pharma Mar, S.A. Antitumoral treatments
WO2008080956A1 (fr) * 2006-12-29 2008-07-10 Pharma Mar, S.A. Marqueurs moléculaires de pronostic pour thérapie anticancéreuse à l'aplidine
WO2009002553A1 (fr) * 2007-06-25 2008-12-31 Prolexys Pharmaceuticals, Inc. Procédés de traitement d'un myélome multiple et de cancers résistants
US20100240595A1 (en) * 2007-10-19 2010-09-23 Pharma Mar ,S.A. Improved Antitumoral Treatments
WO2009111698A1 (fr) * 2008-03-07 2009-09-11 Pharma Mar, S.A. Traitements améliorés contre le cancer
NZ589270A (en) * 2008-05-16 2011-12-22 Pharma Mar Sa Multiple myeloma treatments
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
EP0048149B1 (fr) 1980-09-12 1983-11-30 University of Illinois Foundation Antibiotiques, dérivés de ceux-ci, procédé de leur extraction et compositions contenant ceux-ci
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
AU681231B2 (en) * 1993-12-29 1997-08-21 Intarcia Therapeutics, Inc. Methods and compositions for the treatment of a host with a cellular proliferative disease
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
ATE196844T1 (de) * 1996-05-22 2000-10-15 Protarga Inc Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
NZ333428A (en) 1996-07-03 2000-09-29 Mckechnie United Kingdom Ltd Stacking and nesting containers with formations on tops of side walls to enhance stability when containers placed side by side
WO1998017302A1 (fr) 1996-10-24 1998-04-30 The Board Of Trustees Of The University Of Illinois Synthese totale d'analogues amino-hip de didemnine a
CA2269881A1 (fr) 1996-10-24 1998-04-30 The Board Of Trustees Of The University Of Illinois Procedes semi-synthetiques de preparation d'analogues de didemnine
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
JP4327260B2 (ja) * 1997-05-07 2009-09-09 フアルマ・マル・エセ・ア Ｌ型カルシウムチャンネルエンハンサーとしてのアプリジン
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
DE69923322T2 (de) * 1998-07-30 2005-12-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
JP2003500360A (ja) 1999-05-25 2003-01-07 ポイント セラピューティクス， インコーポレイテッド ボロプロリン化合物類を含む抗癌剤
SI1229922T1 (sl) * 1999-11-15 2008-04-30 Pharma Mar Sa Zdravljenje raka z aplidinom
AU2001251498A1 (en) 2000-04-07 2001-10-23 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
WO2002028902A2 (fr) * 2000-10-05 2002-04-11 Immunex Corporation Polypeptides de nectine, polynucleotides, procedes de fabrication et utilisation
MXPA03003230A (es) * 2000-10-12 2004-12-03 Pharma Mar Sa Tratamiento de canceres.
WO2002032374A2 (fr) * 2000-10-18 2002-04-25 Immunex Corporation Methodes de traitement de troubles induits par l'il-18
AU2002219472A1 (en) * 2001-01-02 2002-07-16 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
EP1435991B1 (fr) 2001-10-19 2008-10-15 Pharma Mar, S.A. Utilisation d'aplidine pour le traitement du cancer du pancreas
JP2006519848A (ja) 2003-03-12 2006-08-31 ファルマ・マール・ソシエダード・アノニマ 改良された抗腫瘍治療

Also Published As

Publication number Publication date
RU2005131578A (ru) 2006-01-27
IL170136A (en) 2014-04-30
CA2519789A1 (fr) 2004-09-23
KR101160320B1 (ko) 2012-06-26
JP2006519828A (ja) 2006-08-31
US20070149445A9 (en) 2007-06-28
JP4584245B2 (ja) 2010-11-17
EP1603584A1 (fr) 2005-12-14
AU2004218883B2 (en) 2009-10-01
CY1108599T1 (el) 2014-04-09
EP1603584B1 (fr) 2008-08-27
MXPA05009742A (es) 2006-05-25
ATE406171T1 (de) 2008-09-15
RU2335294C2 (ru) 2008-10-10
PL1603584T3 (pl) 2009-02-27
CA2519789C (fr) 2012-07-03
PT1603584E (pt) 2008-11-21
AU2004218883A1 (en) 2004-09-23
KR20060006779A (ko) 2006-01-19
WO2004080477A8 (fr) 2004-11-11
US20060172926A1 (en) 2006-08-03
DE602004016126D1 (de) 2008-10-09
WO2004080477A1 (fr) 2004-09-23
ES2312979T3 (es) 2009-03-01
NO334264B1 (no) 2014-01-20
NZ541611A (en) 2008-04-30
NO20054668L (no) 2005-10-11
US7381703B2 (en) 2008-06-03
SI1603584T1 (sl) 2009-02-28

Similar Documents

Publication Publication Date Title
CY1108599T1 (el) Η απλιδινη στην αντιμετωπιση του πολλαπλου μυελωματος
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
ATE461217T1 (de) Glp-1-verbindungen
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
ATE474617T1 (de) Medizinproduktsysteme
NO20055130L (no) Aminocykloheksyleter-forbindelser og deres anvendelse
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
TR201906789T4 (tr) Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları.
CY1108843T1 (el) 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων
DE60327103D1 (de) Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer
NO20053947D0 (no) Forbedrede antitumorale behandlinger.
TW200716088A (en) Formulations and methods for treating amyloidosis
UA88655C2 (ru) S-миртазапин для лечения прилива крови
SE0301650D0 (sv) Novel compounds
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme
DK1530462T3 (da) 1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens
CY1109803T1 (el) Φαρμακευτικες συνθεσεις που βασιζονται σε ανταγωνιστες νκ2 για παιδιατρικη χρηση
DK2845594T3 (da) Anvendelse af dihydroimidazoloner til behandlingen af hunde.
BRPI0417265A (pt) composição farmacêutica compreendendo um princìpio ativo e sulfobetaìna
ATE369136T1 (de) Therapeutische behandlung
DE60322942D1 (de) Textilbehandlung
DK1537132T3 (da) Salt af mortin-6-glucuronid
DE50309647D1 (de) Ng fibrotischer erkrankungen
DK1523985T3 (da) Ikke-radioaktivt strontiumholdigt middel til behandling af kræft